MCKQueued from the May 25, 2026 S&P 500 market-cap snapshot ranks 101-125.

McKesson

McKesson distributes pharmaceuticals, medical supplies, and health care technology products and services across provider, pharmacy, and life-sciences channels.

CompaniesMarketCap Product analyses

Metadata

Where this company sits

Ticker: MCK
Rank snapshot: ≈ 112
Sector: Health Care
Industry: Health Care Distributors
Region: United States
Index: S&P 500 · Top 125 by market cap

Metrics

Scoring view

Every metric is paired with a short rationale. The numbers are deliberate, not divine.

Moat

82.0/10

Large regulated distribution networks, national customer relationships, supplier contracts, working-capital scale, and embedded provider workflows create a strong operational moat even though much of the software layer is technically replaceable.

Decentralizability

38.0/10

Facility inventory and last-mile logistics software can be opened or federated, but national pharmaceutical distribution requires regulated purchasing, compliance, cold chain, recall processes, supplier trust, and high fulfillment reliability.

Profitability

58.0/10

McKesson is profitable and cash-generative, but distribution economics remain structurally low-margin relative to many software or branded health care businesses.

Price / Earnings

20.0x

StockAnalysis reported a trailing P/E ratio of 19.97 for MCK around the May 2026 review window.

Market cap

$92.1B

CompaniesMarketCap listed McKesson at approximately $92.08 billion in market capitalization in May 2026.

Freed-up capital potential

$0.0

Derived from market cap, moat resistance, decentralizability, and profitability. It is a directional estimate of value capture that could come under pressure if open alternatives compound.

Narrative

Why the company matters

A short editorial overview plus the current thesis on moat strength and decentralization pressure.

Business footprint

McKesson is one of the largest U.S. health care distributors, with core activity in pharmaceutical distribution, specialty products, medical-surgical supplies, and provider-facing services.

Its Medical-Surgical business serves health care facilities through a national distribution network, online ordering, inventory tools, and a catalog of more than 300,000 products.

Registry relevance

The company sits in a low-margin but high-scale coordination layer: moving regulated products reliably, validating availability, and embedding itself into procurement workflows.

Open-source logistics systems can reduce dependence on proprietary ordering and inventory software, but replacing McKesson's physical distribution reach would require major supplier contracts, compliance capacity, credit, cold-chain operations, and local fulfillment density.

Moat reading

McKesson's moat is built less on unique software and more on scale, contracts, working capital, regulatory trust, and operational density. The annual report and product materials point to enormous pharmaceutical distribution volumes and a broad medical-surgical fulfillment network.

The strongest lock-in comes from reliability expectations in health care procurement. Pharmacies, clinics, and hospitals need availability, traceability, recall handling, credit terms, and compliant delivery, which makes switching away from an incumbent distributor operationally risky.

Decentralization reading

The software layer is moderately decentralizable: ordering, stock visibility, replenishment workflows, and facility inventory management can be handled by open-source tools such as OpenBoxes or OpenLMIS in narrower settings.

The physical distribution layer is harder to decentralize. A credible decentralized model would likely start with federated local inventory pools, cooperative buying groups, and open logistics software before challenging national pharmaceutical wholesaling at scale.

Products

Where the moat actually touches users

These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 3 structured disruption concepts across the current product set.

3 disruption concepts tracked0 documented exceptions

Pharmaceutical distribution

Health care distribution

1 concept

McKesson distributes branded, generic, specialty, biosimilar, over-the-counter, and other health care products to pharmacies, hospitals, clinics, long-term care centers, and other institutions.

Open analysis

McKesson Medical-Surgical

Medical supply distribution and ordering

2 concepts

McKesson Medical-Surgical provides wholesale medical supplies, pharmaceuticals, private-label products, online ordering, tracking, and distribution services to health care facilities.

Open analysis

Technology waves

Strategic lenses

These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.

Microfactories and automated mini-home production

Small, software-defined manufacturing cells could make localized production less eccentric and more default.

• Products with heavy branding but generic bill-of-materials profiles look increasingly vulnerable.
• Logistics moats still matter, but their margin for arrogance should narrow.
• Open-source production recipes can pressure both price and product differentiation.

Bitcoin and Lightning as coordination rails

Proof-of-work economics, programmable payment flows, and anti-spam pricing make more digital systems capable of rewarding signal while resisting abuse.

• Platforms that monetize gatekeeping could face pressure from protocol-native payment and reputation layers.
• Micropayments can replace some ad-funded or subscription-heavy distribution models.
• Open systems with credible anti-spam economics deserve a higher decentralizability score than legacy software assumptions suggest.

Paper trail